Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx Pharmaceutical Stock Forecast

Stock Price Forecast

The 19 analysts that cover Ultragenyx Pharmaceutical stock have a consensus rating of "Strong Buy" and an average price target of $66.32, which forecasts a 191.90% increase in the stock price over the next year. The lowest target is $25 and the highest is $117.

Price Target: $66.32 (+191.90%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$25	$66.32	$63	$117
Change	+10.04%	+191.90%	+177.29%	+414.96%

Analyst Ratings

The average analyst rating for Ultragenyx Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Sep '25	Oct '25	Nov '25	Dec '25	Jan '26	Feb '26
Strong Buy	5	5	6	7	8	7
Buy	8	8	8	11	11	11
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	14	14	15	19	20	19

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Whitney Ijem Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $128 → $79	Strong Buy	Maintains	$128 → $79	+247.71%	Feb 18, 2026
Liisa Bayko Evercore ISI Group	Evercore ISI Group	Buy Maintains $37 → $34	Buy	Maintains	$37 → $34	+49.65%	Feb 18, 2026
Liisa Bayko Evercore ISI Group	Evercore ISI Group	Buy Maintains $39 → $37	Buy	Maintains	$39 → $37	+62.85%	Feb 17, 2026
Laura Chico Wedbush	Wedbush	Hold Reiterates $25	Hold	Reiterates	$25	+10.04%	Feb 17, 2026
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $60 → $50	Strong Buy	Maintains	$60 → $50	+120.07%	Feb 17, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

788.98M

Increased by 17.23%

from 673.00M

Revenue Next Year

1.07B

Increased by 36.13%

from 788.98M

EPS This Year

-3.96

from -5.83

EPS Next Year

-1.39

from -3.96

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	351.41M	363.33M	434.25M	560.23M	673.00M	788.98M	1.07B
Revenue Growth	29.66%	3.39%	19.52%	29.01%	20.13%	17.23%	36.13%
EPS	-6.70	-10.12	-8.25	-6.29	-5.83	-3.96	-1.39
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	22	17

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030
High	948.8M	1.5B
Avg	789.0M	1.1B
Low	597.5M	858.7M

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030
High	41.0%	89.5%
Avg	17.2%	36.1%
Low	-11.2%	8.8%

EPS Forecast

EPS	2026	2027	2028	2029	2030
High	-1.22	2.29
Avg	-3.96	-1.39
Low	-6.32	-3.78

EPS Growth

EPS Growth	2026	2027	2028	2029	2030
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.